Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.
Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of hematological malignancies and solid tumors.Poseida Therapeutics was founded in 2014 and is headquartered in San Diego, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 22, 2019 | Series C | $142M | 1 | — | — | Detail |
Apr 3, 2018 | Series B | $30.50M | 1 | — | — | Detail |
Aug 2, 2017 | Series A | $11.16M | 1 | Malin Corporation | — | Detail |
Dec 23, 2015 | Series A | $23M | 1 | Malin Corporation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Malin Corporation | — | Series C |